Subscribe: Market Wire - Pharmaceuticals and Biotech: Drugs
http://img.marketwire.com/rss/mwPBDR.rss
Added By: Feedage Forager Feedage Grade B rated
Language: English
Tags:
announced  company  december  diet  marketwired dec  marketwired nov  marketwired november  marketwired  medical  new  nov  november  today 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Market Wire - Pharmaceuticals and Biotech: Drugs

Marketwired - Drugs



Marketwired - Drugs



Last Build Date: Sat, 03 Dec 2016 12:41:36 EST

Copyright: Copyright: (C) Marketwired
 



Trillium Presents Initial Data From Ongoing Study of TTI-621 in Patients With Advanced Hematologic Malignancies at the American Society of Hematology Annual Meeting

Sat, 03 Dec 2016 12:00:00 EST

SAN DIEGO, CALIFORNIA--(Marketwired - Dec. 3, 2016) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today presented data from an ongoing study with its lead drug candidate, TTI-621, in patients with relapsed or refractory hematologic malignancies, at the American Society of Hematology (ASH) 58th Annual Meeting in San Diego.




Diet Doc Offers Appetite Suppressants and Doctor-Supervised Military Diet to Minimize Gradual Weight Gain

Sat, 03 Dec 2016 01:00:00 EST

JACKSON, MS--(Marketwired - December 03, 2016) - Over 78 million Americans are obese and facing health issues like type 2 diabetes, cardiovascular disease and various types of cancer. Many more are overweight and suffering through the consequences of poor lifestyle choices and unbalanced diets. One of the leading causes of unmoderated weight gain is excessive food dependence, or food addiction, which involves the loss of control in moderating food consumption. Scientific evidence consistently indicates that food addiction makes it practically impossible for people to abstain from certain types of food or reduce consumption, even when faced with evident health risks. Many people simply lose control and are unable to moderate the consumption of tasty but fattening foods like sweets and processed snacks.




CSE Conditionally Approves Listing of CannaRoyalty Corp.

Fri, 02 Dec 2016 20:27:13 EST

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Dec. 2, 2016) - Bonanza Blue Corp. ("Bonanza") and Cannabis Royalties & Holdings Corp. ("CRHC") are pleased to announce that the Canadian Securities Exchange (the "CSE") has conditionally approved the listing of the common shares of CannaRoyalty Corp. ("CannaRoyalty") under the trading symbol "CRZ". CannaRoyalty is expected to be the resulting issuer to be created from the previously announced proposed three-cornered amalgamation of CRHC with a wholly-owned subsidiary of Bonanza (the "RTO").




Containing Hazardous Drugs with CSTDs Focus of B. Braun Medical CE Symposium at ASHP

Fri, 02 Dec 2016 10:00:00 EST

BETHLEHEM, PA--(Marketwired - Dec 2, 2016) - Experts will present a panel discussion on "Understand the Evidence and Requirements from USP < 800 > to the NIOSH Universal Testing Draft Protocol" at a B. Braun Medical Inc. sponsored symposium during the American Society of Health-System Pharmacists (ASHP) 51st Midyear Clinical Meeting. The symposium for continuing education credits will be held on Tuesday, Dec. 6, from 11:30 a.m. to 1:00 p.m. at the South Pacific J North Convention Center at Mandalay Bay in Las Vegas.




New Advanced Antimicrobial Stewardship Solution from Wolters Kluwer Helps Healthcare Organizations Improve Clinical Outcomes, Reduce Costs

Fri, 02 Dec 2016 09:30:00 EST

Expanded Pharmacy OneSource Sentri7 Offering Powers High-Performing Antimicrobial Stewardship Programs to Address Growing Concerns Over Resistant Organisms




Chief Science Officer Explains How Digipath Labs Enables True, Standardized Definition and Identification of Cannabis Strains

Fri, 02 Dec 2016 09:00:00 EST

LAS VEGAS, NV--(Marketwired - Dec 2, 2016) - Digipath, Inc. (OTCQB: DIGP) ("Digipath" or the "Company"), an independent cannabis lab testing and media firm, is pleased to provide an overview of Digipath Labs' vision for establishing classification of cannabis strains based on science and not colloquialism.




eWellness Announces Signing of Initial Third Party PT Clinic for its PHZIO Telemedicine Platform

Fri, 02 Dec 2016 08:45:00 EST

CULVER CITY, CA--(Marketwired - Dec 2, 2016) - eWellness Healthcare Corporation, (OTCQB: EWLL) is the first physical therapy telemedicine company to offer insurance reimbursable real-time distance monitored physical therapy (PT) treatments. The Company is pleased to announce the Company successfully signed its initial 3rd party PT clinic for the use of its PHZIO Tele- rehabilitation Platform. The agreement is with Back to Motion PT located in Denver Colorado. Back to Motion PT is one of our current universe of up to 30 beta site PT clinics to begin using our PHZIO system. The Company has a significant backlog of PT clinics who have indicated a high interest in using our PHZIO platform.




Diet Doc Releases Doctor-Recommended Program to Lose Weight Fast With the Mediterranean Diet

Fri, 02 Dec 2016 01:00:00 EST

CHARLESTON, WV--(Marketwired - December 02, 2016) - Throughout the U.S., millions of individuals are overweight or obese, facing health problems like heart disease, type 2 diabetes, and metabolic syndrome (MetS). MetS refers to a cluster of risk factors that raise the chances of heart disease and other health issues like diabetes and stroke. It involves specific signs ranging from elevated triglycerides (and poor lipid balance in general), elevated blood pressure, elevated fasting glucose and an excess of body fat. An individual with three or more of the following metabolic risk factors may be diagnosed with MetS:




Dr. Rao of Diet Doc Warns That Going Gluten-Free Can Inadvertently Result in a Lack of Proper Nutrition

Fri, 02 Dec 2016 01:00:00 EST

BURLINGTON, VT--(Marketwired - December 02, 2016) - A new report by Harvard Medical School states that gluten-free dieting can easily result in a lack of proper nutrition, particularly for those without celiac disease. Gluten is a protein which is found in certain grains such as, wheat, rye and barley. It has been used in a variety of pastas, breads, cereals and other processed foods to ensure that they maintain their form. According to the Celiac Disease Foundation, gluten acts as a trigger for those who are prone to having the gastrointestinal disorder, celiac disease, though it is primarily hereditary. Celiac disease may lead to a host of other inflammatory, gluten-related conditions which may stem from gluten sensitivity or wheat allergies. Researchers are concerned that consumers who are eager to drop gluten from their diets may be lacking the essential B Vitamins, folate and fiber that comes from consuming fortified breads, cereals and pastas.




Avantor Unveils New Brand Identity

Thu, 01 Dec 2016 12:30:00 EST

Corporate logo and brand identity are reflective of Avantor's position as a growing, global supplier of high-purity life sciences and advanced technologies materials




Quark Venture Invests $4 Million in A New Technology That Harnesses the Body's Natural Immune System to Combat Disease

Thu, 01 Dec 2016 12:27:45 EST

GV and Quark Venture Join NanoDimension, Polaris Partners in supporting SQZ Biotech's breakthrough cell engineering technology




Blue Diamond Ventures, Inc. unveils Strategic Plan for Cannabis Real Estate

Thu, 01 Dec 2016 10:44:05 EST

DENVER, CO--(Marketwired - Dec 1, 2016) - Blue Diamond Ventures Inc. (OTC PINK: BLDV) today announces its Cannabis Real Estate Strategy for 2017, including projects in Michigan, Oregon and Canada.




The Alliance for Regenerative Medicine Commends Passage of 21st Century Cures Act, Inclusion of Regenerative Medicine-Specific Provisions

Thu, 01 Dec 2016 10:31:01 EST

WASHINGTON, DC--(Marketwired - Dec 1, 2016) -  The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cellular therapies and broader regenerative medicine sector, commends the U.S. House of Representatives' bipartisan passage of the 21st Century Cures Act.




IntelGenx Strengthens Partnership with Chemo Group by Signing a Co-Development Term Sheet for an Additional Product

Thu, 01 Dec 2016 09:56:08 EST

SAINT-LAURENT, CANADA--(Marketwired - Dec. 1, 2016) - IntelGenx Corp., (TSX VENTURE:IGX)(OTCQX:IGXT), today strengthened its relationship with Chemo Group ("Chemo") by signing a term sheet for the co-development and commercialization of a generic tablet in the area of CNS (central nervous system) on a worldwide basis. According to Global Data, worldwide sales in 2015 of the CNS related product exceeded $4 billion.




Laguna Blends Engages CFN Media to Build Audience of Investors and Elevate Brand

Thu, 01 Dec 2016 09:29:29 EST

SEATTLE, WA--(Marketwired - Dec 1, 2016) - CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, today announced that Laguna Blends Inc. (CSE: LAG) (OTC PINK: LAGBF) has agreed to conduct a four (4) month investor and market visibility program beginning on December 1, 2016.




Genetic Technologies Announces Offering of USD 6.0 Million of American Depository Shares

Thu, 01 Dec 2016 09:07:53 EST

MELBOURNE, AUSTRALIA--(Marketwired - Dec 1, 2016) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company"), a molecular diagnostics company and provider of BREVAGenplus®, a first-in-class, clinically validated risk assessment test for sporadic (non-hereditary) breast cancer, today announced that it has entered into a definitive agreement with U.S. institutional investors, pursuant to which the investors have agreed to purchase an aggregate of 4,800,000 American Depositary Shares ("ADSs"), each representing one hundred and fifty (150) of the Company's Ordinary Shares, at a weighted average price of $1.25 per ADS. The Company will receive gross proceeds of approximately USD 6.0 million, before deducting customary offering expenses.




Oculus Innovative Sciences One Ups Itself, Meets Expectations Yet Again -- SECFilings.com

Thu, 01 Dec 2016 09:02:33 EST

REDONDO BEACH, CA--(Marketwired - Dec 1, 2016) -  SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article examining the turnaround efforts of Oculus Innovative Sciences (NASDAQ: OCLS).




Ontario, Canada and South Korea Create $100M Global Commercialization Partnership

Thu, 01 Dec 2016 09:00:00 EST

TORONTO, ON--(Marketwired - December 01, 2016) - Today MaRS Innovation (MI) and the Korea Health Industry Development Institute (KHIDI) signed a five year global partnership agreement to commercialize the latest advances in biomedical and healthcare innovations which is expected to generate new startups worth over $100M.




GeoVax Observes World AIDS Day

Thu, 01 Dec 2016 09:00:00 EST

Everyone Encouraged to Get Tested for HIV




PharmaCyte Biotech Moves Closer to Enrolling Patients in Pancreatic Cancer Clinical Trial

Thu, 01 Dec 2016 09:00:00 EST

Company Aiming to Produce 6-Month Breakthrough Data




Crystal Research Associates, LLC Issues Executive Informational Overview on Hemispherx Biopharma, Inc.

Thu, 01 Dec 2016 08:30:00 EST

NEW YORK, NY--(Marketwired - December 01, 2016) - Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview® (EIO) on Hemispherx Biopharma, Inc. (NYSE MKT: HEB). The full 60-page report is available on Crystal Research Associates' website at www.crystalra.com.




Atossa Genetics to Present at the 9th Annual LD Micro Main Event Conference on December 7, 2016

Thu, 01 Dec 2016 08:00:00 EST

SEATTLE, WA--(Marketwired - Dec 1, 2016) - Atossa Genetics, Inc. (NASDAQ: ATOS) announced today that Kyle Guse, CFO and General Counsel, will be a featured presenter at the 9th annual LD Micro Main Event Conference on December 7, 2016 at 12:30pm PST, Track 4, at the Luxe Sunset Hotel in Los Angeles, CA. Management will also be available for one-on-one meetings on December 7 and 8, 2016.




Pieris Pharmaceuticals Appoints Claude Knopf as Chief Business Officer

Thu, 01 Dec 2016 08:00:00 EST

BOSTON, MA--(Marketwired - December 01, 2016) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer and other diseases, today announced that it has appointed Claude Knopf as Senior Vice President and Chief Business Officer. Mr. Knopf is an accomplished executive in the biotech industry and brings to Pieris a demonstrable track record of success in strategy, corporate development, licensing, alliance management, marketing and sales spanning more than two decades.




Aequus Obtains Public Reimbursement for Vistitan in Two Additional Provinces: Alberta and Manitoba

Thu, 01 Dec 2016 08:00:00 EST

VANCOUVER, BC--(Marketwired - December 01, 2016) - Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that it has successfully obtained provincial formulary coverage from Alberta Health and Manitoba Health for VistitanT (bimatoprost 0.03% w/v, ophthalmic solution). Alberta Health have additionally listed VistitanT as interchangeable to Lumigan RC® for the purposes of its formulary coverage, giving Aequus rapid access to an existing market in Alberta. According to IMS data, Lumigan RC® sold over CND$5M in Alberta and Manitoba combined in 2015.




Stellar Biotechnologies to Present at the LD Micro Main Event Investor Conference

Thu, 01 Dec 2016 07:45:00 EST

LOS ANGELES, CA--(Marketwired - Dec 1, 2016) - Stellar Biotechnologies, Inc. (NASDAQ: SBOT), the leader in sustainable manufacture of a key protein utilized in multiple immunotherapy development pipelines targeting cancers, Alzheimer's and lupus, among other diseases, today announced that Stellar President and CEO Frank Oakes will present at the 9th Annual LD Micro Main Event investor conference to be held December 6-8, 2016 in Los Angeles, California.




Xtalks Announces its December 2016 Webinars

Thu, 01 Dec 2016 07:00:00 EST

TORONTO, ON--(Marketwired - December 01, 2016) - Upcoming free, educational webinars from Xtalks Life Sciences will feature topics on ICH E6 (R2),Sales Enablement Strategy, Immunotherapy, Big Data, Orphan Drug Development and Remote Monitoring.




Dynavax to Webcast Cancer R&D Day on December 9, 2016

Thu, 01 Dec 2016 07:00:00 EST

BERKELEY, CA--(Marketwired - December 01, 2016) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the company will hold a Research and Development (R&D) Day in New York City next week where it will showcase its immuno-oncology program. The event, which is for institutional investors, will be webcast live and can be found in the Investor section of the company's website at www.dynavax.com.




USEI Announces its 3rd 20% Stock Dividend for Shareholders of Record on the Record Date

Thu, 01 Dec 2016 06:00:00 EST

SANTA CLARITA, CA--(Marketwired - Dec 1, 2016) - USEI CANNABIS initiatives CORP, a wholly owned subsidiary of US ENERGY INITIATIVES CORPORATION, INC. (OTC PINK: USEI) is pleased to announce today that the Directors of USEI have approved a 20% restricted common stock dividend for shareholders of record on the company's record dated (estimated to be December 15th 2016). Management will be filing a Corporation Action with FINRA to issue a restricted stock dividend. The dividend will be added to the shareholders' existing shares on the pay date. Details of the transaction will become available to the shareholders once FINRA has approved the Corporate Action.




Vernalis plc: AGM Statement

Thu, 01 Dec 2016 02:00:00 EST

WINNERSH, UNITED KINGDOM--(Marketwired - Dec 1, 2016) - Vernalis plc (LSE: VER) (OTC PINK: VNLPY)




Diet Doc's Medical Director Finds No Evidence to Support The Popular Alkaline Diet

Thu, 01 Dec 2016 01:00:00 EST

WASHINGTON, DC--(Marketwired - December 01, 2016) - The Alkaline Diet is purported to change the body to a healthy PH state through changes in diet. The concept of alkalizing to improve health has been around for some time, however much of the research shows that many of these claims are baseless. Dr. Nishant Rao -- Medical Director of nationally recognized medical weight loss program, Diet Doc, states that, "One of the greatest problems with this concept is that it isn't very scientifically sound. The body maintains an extremely narrow pH window, with blood pH ranging between 7.35 and 7.45. This means that even as you consume highly alkaline foods, your body will always regulate blood pH in this narrow window." Dr. Rao also explains that, "If you consumed a high amount of acidic food, your body would offset it by buffering blood pH so that the actual levels never change."




B. Braun Announces Interoperability Collaboration with Omnicell's(R) Performance Center and IV AutomationTechnology

Wed, 30 Nov 2016 17:55:00 EST

BETHLEHEM, PA--(Marketwired - Nov 30, 2016) - B. Braun Medical Inc. and Omnicell, Inc. (NASDAQ: OMCL), today announced they are working together to increase system interoperability to help decrease the time and clinical support needed to manage IV Infusions and IV compounding.




ViaDerma, Inc. Clinical Studies Abroad in Europe, the Middle East and Asia Show Promising Results & Leads to Private Label Discussions

Wed, 30 Nov 2016 17:49:18 EST

Clinical Tests Show Dramatic Success of ViaDerma's Proprietary Delivery System Combined with FDA Approved Drugs for Wound Healing with Localized Wound Treatment -- This Leads to Early-Stage discussions with two Pharmaceutical Companies to Private Label Viabecline for Distribution in Europe, Asia, the Middle East, and North Africa




CAPS to present new 100 percent release testing quality assurance program at ASHP

Wed, 30 Nov 2016 15:20:00 EST

IRVINE, CA--(Marketwired - Nov 30, 2016) - Central Admixture Pharmacy Services, Inc. (CAPS®) will present its new quality assurance program requiring 100 percent release testing of all of its compounded drugs and other products at this year's American Society of Health-System Pharmacists (ASHP) 51st Midyear Clinical Meeting.




SafetyChain Software to Showcase Food Safety & Quality Management Solutions at Food Safety Consortium in Schaumburg, IL

Wed, 30 Nov 2016 13:58:03 EST

Visit SafetyChain at Food Safety Tech's Annual Food Safety Consortium to learn how companies are improving their food safety and quality operations with SafetyChain




AXIM Biotech Looks to Unlock Value in 2017 -- SECFilings.com

Wed, 30 Nov 2016 12:00:00 EST

REDONDO BEACH, CA--(Marketwired - Nov 30, 2016) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces an article discussing the major advancements in 2016 for AXIM Biotechnologies (OTCQB: AXIM) and the potential catalysts for the company in the upcoming year.




Aphria Announces Closing of Bought Deal Financing

Wed, 30 Nov 2016 11:14:43 EST

LEAMINGTON, ONTARIO--(Marketwired - Nov. 30, 2016) -




B. Braun Medical to Introduce Comprehensive Parenteral Nutrition Program at ASHP

Wed, 30 Nov 2016 10:10:00 EST

Company also to showcase diverse portfolio of pharmaceutical, drug delivery products




TEC Edmonton's Randy Yatscoff wins Startup Canada National Lifetime Achievement award

Wed, 30 Nov 2016 10:00:00 EST

Adam Chowaniec award recognizes outstanding impact and legacy in Canadian Entrepreneurship




Advantis Corp. Amstercan Sales Increase Three-Fold

Wed, 30 Nov 2016 09:26:00 EST

NEWPORT BEACH, CA--(Marketwired - Nov 30, 2016) - ADVANTIS CORPORATION (OTC PINK: ADVT), announced that Speedweed, California's Largest marijuana delivery service, placed their first product reorder this week. The company has tripled its previous order and expects to purchase two to three hundred Amstercans each month.




FDA Grants Diazyme 510(k) Clearance to Market Its Direct HbA1c (Enzymatic, On-Board Lysis) Assay for Clinical Chemistry Analyzers

Wed, 30 Nov 2016 09:00:00 EST

SAN DIEGO, CA--(Marketwired - November 30, 2016) - Diazyme Laboratories today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to market its Direct HbA1c assay (Enzymatic, On-Board Lysis). HbA1c refers to glycated hemoglobin which occurs when hemoglobin, a protein within red blood cells that transports oxygen through the body, joins with glucose in the blood, thereby becoming glycated. Measuring HbA1c allows clinicians to get an overall picture of what a patient's average blood sugar levels have been over a period of months. This measurement is the gold standard in allowing clinicians to track patients with diabetes.




ADV-CARE Releases Updated Mobile App for its Canadian Online Pharmacy

Wed, 30 Nov 2016 09:00:00 EST

TORONTO, ON--(Marketwired - November 30, 2016) - Canadian-based mail-order, online pharmacy, ADV-CARE Pharmacy, (www.advpharmacy.com / www.adv-care.com), has updated its mobile, smartphone app that provides patients current prices, the ability to fill/refill their prescriptions and other services while on the go, any-time, any-place.




Manufacturing Leadership Forums Continue to Drive the Manufacturing Intelligence & Analytics Conversation

Wed, 30 Nov 2016 08:30:00 EST

Premiere Educational Events Concluded in Houston, Texas and Liverpool, England




Hamilton Thorne to Present at the 2016 LD Micro Main Event

Wed, 30 Nov 2016 08:30:00 EST

BEVERLY, MA and TORONTO, ON--(Marketwired - Nov 30, 2016) - Hamilton Thorne Ltd. (TSX VENTURE: HTL), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART) and developmental biology research markets announced today announced that it will be presenting at the 9th annual LD Micro Main Event (www.ldmicro.com), on Wednesday, December 6, 2016 at 2:30 pm Pacific Time (5:30 pm Eastern Time), at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.




American Green Integrates World Class Biometrics in the American Green Machine

Wed, 30 Nov 2016 08:00:00 EST

Creates a Better-Than-Human Standard for Verification




Aequus Provides Q3 2016 Financial Highlights With Substantial Increase in Quarter Over Quarter Revenues

Wed, 30 Nov 2016 08:00:00 EST

VANCOUVER, BC--(Marketwired - November 30, 2016) - Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today provided a corporate update and has filed its financial results for the three months ended September 30, 2016, which is available on www.sedar.com. Unless otherwise noted, all figures are in Canadian currency.




Helix BioPharma Corp. Accelerates Escalation of L-DOS47 Dosing in the U.S. Phase I Study

Wed, 30 Nov 2016 07:30:00 EST

TORONTO, ON--(Marketwired - Nov 30, 2016) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that after reviewing safety data from the Phase I/II study of L-DOS47 in non-squamous non-small cell lung cancer (LDOS002), the U.S. Food and Drug Administration ("FDA") has accepted an accelerated escalation scheme for L-DOS47 dosing in the U.S. Phase I study (LDOS001) up to 12µg/kg in combination with pemetrexed/carboplatin.




Dynavax to Present Clinical Data from Immuno-oncology Product Candidate, SD-101

Wed, 30 Nov 2016 07:00:00 EST

Data to be Presented at ASH Annual Meeting on Sunday, December 4th, in San Diego




Delivra Reports Record Q3 Revenues and Licensing Agreement for the Transdermal Delivery of Medical Cannabis During the Quarter

Wed, 30 Nov 2016 07:00:00 EST

TORONTO, ON--(Marketwired - November 30, 2016) - Delivra Corp. (TSX VENTURE: DVA) ("Delivra" or the "Company") reported its financial results for the three and nine month periods ended September 30, 2016. All figures are reported in CDN dollars ($), unless otherwise indicated. Delivra's financial statements are prepared in accordance with International Financial Reporting Standards ("IFRS").




OrganiGram Completes Site Design for Annual Production of 26,000 kg

Wed, 30 Nov 2016 06:00:00 EST

MONCTON, NEW BRUNSWICK--(Marketwired - Nov. 30, 2016) - OrganiGram Holdings Inc. (TSX VENTURE:OGI)(OTCQB:OGRMF) (the "Company") is pleased to announce it has completed the design work related to a proposed addition to the onsite production building located at 35 English Drive in Moncton, NB. The preliminary design and drawings provide sufficient additional space to facilitate incremental production capacity of approximately 9,000 kg per year. When combined with the previously announced and ongoing expansions to both buildings, this new addition brings the total proposed production capacity at OrganiGram to approximately 26,000 kg per year.




Diet Doc Offers Powerful Medical Weight Loss Program to Maximize Effectiveness of Low FODMAP Diet

Wed, 30 Nov 2016 01:00:00 EST

BURLINGTON, VT--(Marketwired - November 30, 2016) - In the United States, there is no shortage of fad diets and weight loss supplements promising a slimmer body through rapid weight loss. Around 45 million Americans diet each year, spending an estimated $33 billion annually on weight loss products. Nevertheless, nearly two-thirds of Americans are overweight or obese, facing serious health issues like diabetes, high blood pressure, elevated cholesterol, heart disease and more. Consistent regulation of physical activity and calories consumed is crucial. However, many weight loss programs and supplements can do more harm than good, particularly as dietary supplements do not require U.S. Food and Drug Administration (FDA) before being marketed. Diligently choosing diet supplements and weight loss programs, therefore, is important.




Nutritional High Corporate Update

Tue, 29 Nov 2016 13:43:15 EST

TORONTO, ONTARIO--(Marketwired - Nov. 29, 2016) - Nutritional High International Inc. (the "Company" or "Nutritional High") (CSE:EAT)(OTCQB:SPLIF)(FRANKFURT:2NU) announces the issuance of 315,000 stock options.




ZIVO Bioscience Granted New US Patent for Healthy Cholesterol Balance

Tue, 29 Nov 2016 13:27:03 EST

KEEGO HARBOR, MI--(Marketwired - Nov 29, 2016) - ZIVO Bioscience, Inc. (OTCQB: ZIVO) announced today that it received notice of a fourth US patent issued on November 17, 2016 covering the novel cholesterol management properties of the bioactive components extracted from its proprietary algal culture.




Natural Remedy for Common Cold, Myrtol(R) 300 Available on Walmart Marketplace

Tue, 29 Nov 2016 12:43:11 EST

Recently Launched in the U.S., Myrtol(R) 300 Targets Value Buyers on Expanding E-commerce Platform




3M ESPE, DENTSPLY, Kerr Lead U.S. Dental Materials Market Due to Extensive Product Portfolios

Tue, 29 Nov 2016 12:30:52 EST

The U.S. dental materials market is projected to exceed $1.8 billion by 2023; the market includes dental cements, impression materials, direct and temporary restoratives, bonding agents, core build-up materials and anesthetic materials




Medical Marijuana, Inc.'s Investment Axim(R) Biotech Files IP Application on Proprietary Method to Extract High-Purity THC

Tue, 29 Nov 2016 12:00:00 EST

Company's Major Investment company Announces Filing of Protection for Proprietary Method of THC Extraction that will Achieve Highest THC Purity Level on the Market




New Tenant Approved to Begin Growing in GrowCo's First Greenhouse

Tue, 29 Nov 2016 11:13:26 EST

DENVER, CO--(Marketwired - Nov 29, 2016) - GrowCo, Inc. (GrowCo), an indirect subsidiary of Two Rivers Water & Farming Company (Two Rivers) (OTCQB: TURV), announced that a new tenant, a sublease of our existing tenant, was approved on November 28, 2016 by the Pueblo County Liquor and Marijuana Licensing Board to immediately begin growing marijuana in GrowCo's first greenhouse located in Pueblo County, Colorado.




Viable Canadian Alzheimer's Treatment Halted

Tue, 29 Nov 2016 10:00:00 EST

Affordable Alternative Could Be Available in Months




PCI Synthesis Wins Best NCE Manufacturer in 2016

Tue, 29 Nov 2016 09:15:00 EST

2016 saw more industry recognition and new lines of business




Vaxil Reports Preliminary Data From Checkpoint Inhibitors in Combination With Immucin(TM)

Tue, 29 Nov 2016 09:00:00 EST

TORONTO, ON and REHOVOT, ISRAEL--(Marketwired - November 29, 2016) - VAXIL BIO LTD. (TSX VENTURE: VXL) is pleased to report preliminary pre-clinical results demonstrating anti-cancer activity of ImmucinT in combination with checkpoint inhibitors. Furthermore, Vaxil's scientists have made significant progress for Orphan Designated product ImmucinT in demonstrating its ability to act as a neo-antigen, with potential to strongly stimulate the immune system.




APC Invents Quantitative Method for Assessing Pattern of Antibody Labeling Impacting the Emerging, Rapidly Growing Market for Antibody-Drug Conjugates (ADC)

Tue, 29 Nov 2016 09:00:00 EST

VANCOUVER, BC--(Marketwired - November 29, 2016) - Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE: APC) (FRANKFURT: 0E8) is pleased to announce that it has invented a measurable basis for evaluating antibody labeling that provides key information on the pattern of labeling. The technology provides a means of sorting labeling entities according to the degree of selective labeling resulting from modification of a target antibody for conjugation. The methodology produces a rank order of candidate antibodies carrying antibody connectors for linkage to payloads such as drugs or toxins which should aid decision-making in ADC development. Immense growth is expected for the therapeutic antibody market which is estimated to reach nearly $125 Billion USD by the year 2020 (The therapeutic monoclonal antibody market: Ecker et al. MAbs 2015, Volume 7, ppgs 9-14.).




BriaCell Files a Patent Application for its Companion Diagnostic Platform to complement BriaVax(TM)

Tue, 29 Nov 2016 08:30:00 EST

BERKELEY, CA and VANCOUVER, BC--(Marketwired - November 29, 2016) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), a clinical-stage immuno-oncology company dedicated to the development of immuno-oncology treatments, is pleased to announce that it has filed a patent application with the U.S. Patent and Trademark Office (USPTO) as basis for potential future commercialization of tests for identifying patients with a high likelihood of responding favorably to the Company's lead product candidate, BriaVaxT, and/or other whole-cell cancer vaccines.




Phase 4 Pharmaceutical Studies Lean on Medical Affairs for Strategic Planning

Tue, 29 Nov 2016 08:17:00 EST

RESEARCH TRIANGLE PARK, NC--(Marketwired - November 29, 2016) - Medical affairs functions are an ideal candidate to head post-marketing study strategy, according to new research published by pharmaceutical business intelligence firm Cutting Edge Information.




BioVie Submits Investigational New Drug Application for BIV201 for Treating Refractory Ascites due to Liver Cirrhosis

Tue, 29 Nov 2016 08:00:00 EST

Anticipates Initiation of US Clinical Trial in 2017




Environmental Assessment Explores Impact of Consolidation in the Healthcare Industry

Tue, 29 Nov 2016 08:00:00 EST

WASHINGTON, DC--(Marketwired - November 29, 2016) - Healthcare organizations will be challenged to prove that the changing healthcare landscape has created an environment in which consolidation actually improves value to consumers. That is the conclusion of Health Care 2020: Consolidation, a new report published by the Healthcare Financial Management Association.




Cronos Group Provides Operational Update and Q3 Financial Results

Tue, 29 Nov 2016 08:00:00 EST

TORONTO, ON--(Marketwired - November 29, 2016) -




Exosome Diagnostics to Participate in Evercore ISI MedTools 2016 Investor Conference

Tue, 29 Nov 2016 07:30:00 EST

CAMBRIDGE, MA--(Marketwired - November 29, 2016) - Exosome Diagnostics, Inc. announced today that John Boyce, President and Chief Executive Officer and the senior management team will be participating in the annual Evercore MedTools Conference being held in Boston on November 30 and December 1, 2016 to meet with potential investors, crossover funds, and strategic partners. Due to the one-on-one investor meeting format of the event, no webcast will be available.




Corbus Pharmaceuticals Commences One-Year Open-Label Extension to its Ongoing Phase 2 Study of Resunab (JBT-101) for Skin-Predominant Dermatomyositis

Tue, 29 Nov 2016 07:30:00 EST

Dermatomyositis is the 2nd indication to have one year open-label extension study with JBT-101




New Webinar Hosted by Xtalks with Late Breaking Data from the Society for Immunotherapy of Cancer 2016

Tue, 29 Nov 2016 07:00:00 EST

Combinatorial CD8+ and PDL1+ Cell Densities Correlate with Response and Improved Survival in NSCLC Patients Treated with Durvalumab




Trillium Therapeutics Announces Conference Call and Webcast on December 5th to Discuss TTI-621 Data Presented at ASH

Tue, 29 Nov 2016 07:00:00 EST

TORONTO, ONTARIO--(Marketwired - Nov. 29, 2016) - Trillium Therapeutics Inc. (TSX:TR)(NASDAQ:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it will host a conference call and webcast at 8:30 a.m. ET (5:30 a.m. PT) on Monday, Dec. 5, 2016, to discuss the poster presentation on its lead drug candidate, TTI-621, at the American Society of Hematology (ASH) 58th Annual Meeting in San Diego. Trillium will present initial clinical data from its ongoing TTI-621 hematologic malignancy Phase 1 trial at ASH.




ICC Begins Trading on the TSX Venture Exchange and Provides Operational Update

Tue, 29 Nov 2016 06:00:00 EST

Highlights

- Listing of first licensed producer in South America with industry leading low cost of production.

- Listing of a licensed producer with more than 100 acres of licensed green space for the production of recreational cannabis, cannabinoid extracts for medicinal uses, industrial hemp and by-products.

- Strategic shareholder with extensive experience in large scale agricultural projects in Uruguay.




Genetic Technologies Limited and The University of Melbourne Enter into Exclusive Worldwide License Agreement to Develop Colorectal Cancer Risk Assessment Test

Tue, 29 Nov 2016 05:30:00 EST

MELBOURNE, AUSTRALIA--(Marketwired - Nov 29, 2016) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company"), a molecular diagnostics company and provider of BREVAGenplus®, a first-in-class, clinically validated risk assessment test for sporadic (non-hereditary) breast cancer, today announced the signing of an exclusive worldwide license agreement with The University of Melbourne for the development and commercialisation of a novel colorectal cancer (CRC) risk assessment test.




Diet Doc's Dr. Rao Finds Link Between Poor Nutrition and Obesity

Tue, 29 Nov 2016 01:00:00 EST

ANCHORAGE, AK--(Marketwired - November 29, 2016) - A recent report by the Global Panel on Agriculture and Food Systems for Nutrition found that nearly half the world's population, or 3 billion people, lack proper nutrition due to poor dieting habits and also predicts that within 20 years, one-third of the world's population will be obese. The value of nutritionally balanced eating cannot be understated. Dr. Nishant Rao, Medical Director of Diet Doc -- a nationally recognized medical weight loss program, believes that, "This study highlights an important point about how micro-nutrition, not just total calories can affect health in a way which can lead to obesity."




Golden Leaf Holdings Reports Third Quarter 2016 Unaudited Results and Updates on Developments in the Oregon Market

Mon, 28 Nov 2016 20:50:52 EST

TORONTO, ON--(Marketwired - November 28, 2016) - Golden Leaf Holdings Ltd. ("GLH" or the "Company") (CSE: GLH) (OTCQB: GLDFF), a leading cannabis oil solutions company built around recognized brands, today announced its unaudited interim financial results for the third quarter ended September 30, 2016. Please click here to access the Company's quarterly filing on the SEDAR website.




Presentations at French Society of Plastic, Reconstructive and Aesthetic Surgery Reinforce Benefits of ReCell(R)

Mon, 28 Nov 2016 20:18:57 EST

NORTHRIDGE, CA and PERTH, AUSTRALIA and LONDON, UNITED KINGDOM--(Marketwired - Nov 28, 2016) - Avita Medical Ltd (ASX: AVH) (OTCQX: AVMXY), a regenerative medicine company specializing in new treatments for wounds and skin defects, said today that three presentations about the clinical benefits of its product ReCell® had been delivered at the French Society of Plastic, Reconstructive and Aesthetic Surgery meeting, which took place in Paris, France on 24-26 November.




Xylitol Canada Inc. Issues $477,000 Secured Convertible Debentures and Releases Third Quarter Results

Mon, 28 Nov 2016 18:10:15 EST

TORONTO, ONTARIO--(Marketwired - Nov. 28, 2016) - Xylitol Canada Inc. (TSX VENTURE:XYL) ("Xylitol") is pleased to announce the completion of a secured convertible debenture financing (the "Financing") in the principal amount of $477,000 and was completed as an additional tranche to the secured convertible debentures issued on July 29, 2016 and October 3, 2016 (the "Initial Financings"). The net proceeds of the Financing shall be used as working capital for Xylitol to increase their product sales within the North American natural foods market.




Sermonix Pharmaceuticals to Present Poster on Physician Perceptions of Menopausal SERMs at San Antonio Breast Cancer Symposium

Mon, 28 Nov 2016 16:45:44 EST

COLUMBUS, OH--(Marketwired - Nov 28, 2016) - Sermonix Pharmaceuticals LLC, a specialty pharmaceutical company focused on the development and commercialization of female-specific oncology products, today announced that its poster on physician perceptions of estrogen agonist/antagonists in menopausal health has been accepted for presentation at the San Antonio Breast Cancer Symposium (SABC).




ACCUREXA, INC. (ACXA) and Other Medical Device Companies Add Value for Patients and Investors

Mon, 28 Nov 2016 14:00:00 EST

NEW YORK, NY--(Marketwired - November 28, 2016) - Accurexa, Inc. (OTCQB: ACXA), a small-cap biotech focused on chemotherapy and immunology, is an up-and-coming leader in the neurological therapy space. Currently, Accurexa is working on the targeted delivery of such therapies, specifically the direct delivery of chemotherapeutics that effectively and safely cross the blood-brain barrier, www.accurexa.com.




Progressive Care Increases Revenue by 33% to $1.6 Million during October 2016

Mon, 28 Nov 2016 09:31:56 EST

MIAMI, FL--(Marketwired - November 28, 2016) - Progressive Care Inc. (OTC PINK: RXMD), through its subsidiary Pharmco LLC, a South Florida health services organization and provider of prescription pharmaceuticals specializing in health practice risk management, compounded medications, the sale of anti-retroviral medications and related medication therapy management, and the supply of prescription medications to long term care facilities, announces robust October 2016 sales.




MediCannaVision Inc., a StereoVision Wholly Owned Medical Cannabis and Hemp Florida C Corp Seats Board of Directors

Mon, 28 Nov 2016 09:30:00 EST

LAS VEGAS, NV--(Marketwired - Nov 28, 2016) - StereoVision Entertainment Inc., a publicly traded Nevada company (OTC PINK: SVSN) announced today that MediCannaVision Inc., their wholly owned Florida C Corp, has seated their Board of Directors. MediCannaVision's objective is to acquire and roll up a variety of licensed medical cannabis businesses in population centers and to produce medical cannabis and hemp products.




Hamilton Thorne Reports 18% Sales Increase for the Quarter Ended September 30, 2016

Mon, 28 Nov 2016 09:17:14 EST

BEVERLY, MA and TORONTO, ON--(Marketwired - Nov 28, 2016) - Hamilton Thorne Ltd. (TSX VENTURE: HTL), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART) and developmental biology research markets today reported operational and financial results for the quarter and nine months ended September 30, 2016.




mCig Division Expands International Market

Mon, 28 Nov 2016 09:00:00 EST

Signs Agreement for European Distribution worth $2M over Next Three Years




Lion Biotechnologies Announces New Manufacturing Services Agreement with WuXi AppTec

Mon, 28 Nov 2016 08:00:00 EST

SAN CARLOS, CA--(Marketwired - November 28, 2016) - Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte technology (TIL), announced today that it has entered into a new three-year Manufacturing Services Agreement (MSA) and related statements of work with WuXi AppTec, Inc. (WuXi AppTec) to manufacture and perform services related to the manufacture of the Company's autologous cell therapy products.




Abattis (ATTBF) Targets Emerging Markets with Nutraceutical Business -- CFN Media

Mon, 28 Nov 2016 08:00:00 EST

SEATTLE, WA--(Marketwired - Nov 28, 2016) - CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article covering Abattis Bioceuticals Corp.'s (OTCQB: ATTBF) (CSE: ATT) recent expansion of distribution lines in Asia and how those efforts complement the company's other business lines.




Easton Pharmaceuticals Announces Negotiations For The Filing Of A Medical Marijuana Application In Jamaica Toward Exporting Medicinal Marijuana Into various Countries Including Canada, Mexico, and Brazil

Mon, 28 Nov 2016 08:00:00 EST

TORONTO, ON--(Marketwired - Nov 28, 2016) - Easton Pharmaceuticals, Inc. (OTC PINK: EAPH) announces it has entered into negotiation for the purpose of filing an application in Jamaica for the purpose of growing and exporting medical concentrated Marijuana into various countries including Canada, Mexico, and Brazil.




Acasti Pharma Appoints Linda O'Keefe as Chief Financial Officer

Mon, 28 Nov 2016 08:00:00 EST

LAVAL, QUÉBEC--(Marketwired - Nov. 28, 2016) - Acasti Pharma Inc. (NASDAQ:ACST)(TSX VENTURE:ACST) today announced that Linda O'Keefe has been named chief financial officer. Ms. O'Keefe brings to Acasti over 30 years of financial experience in the life sciences, manufacturing and business service sectors. As part of the company's strategy to operate independently of parent company Neptune Technologies & Bioressources Inc., Mario Paradis has resigned as chief financial officer from Acasti to focus solely on his role as vice president and chief financial officer of Neptune.




Acasti Pharma nomme Linda O'Keefe comme chef de la direction financière

Mon, 28 Nov 2016 08:00:00 EST

LAVAL, QUÉBEC--(Marketwired - 28 nov. 2016) - Acasti Pharma Inc. (NASDAQ:ACST)(TSX CROISSANCE:ACST), annonce aujourd'hui la nomination de Mme Linda O'Keefe à titre de Chef de la direction financière. Mme O'Keefe apporte à Acasti plus de 30 ans d'expérience en finances dans les secteurs des sciences de la vie, de la fabrication et des services d'affaires. Dans le cadre de la stratégie de l'entreprise de fonctionner indépendamment de la société mère Neptune Technologies et Bioressources Inc., M. Mario Paradis a démissionné en tant que chef de la direction financière d'Acasti afin de se concentrer uniquement sur son rôle de Vice-président et Chef de la direction financière de Neptune.




AVIS AUX MÉDIAS : OTTAWA -- Nous vous invitons à soumettre un projet dans la catégorie « Médias »

Mon, 28 Nov 2016 07:59:33 EST

OTTAWA, ON--(Marketwired - 28 novembre 2016) -




MEDIA ADVISORY: OTTAWA -- We invite you to submit a project in the Media Category

Mon, 28 Nov 2016 07:56:43 EST

OTTAWA, ON--(Marketwired - November 28, 2016) -




Upcoming Webinar to Examine Remote Monitoring and Preparing for ICH-GCP E6(R2) at Investigator Sites

Mon, 28 Nov 2016 07:30:00 EST

TORONTO, ON--(Marketwired - November 28, 2016) - On Tuesday, December 13, 2016, Xtalks will host a complimentary webinar featuring presenters Andrew Mitchell, Life Sciences Lead at Intralinks and Dan Sfera, owner of multiple investigator sites, a CRA academy and renowned for his blog, The Clinical Trials Guru. This webinar will focus on how Investigator Sites are preparing for ICH-GCP E6(R2) especially with regards to remote monitoring, sponsor oversight and a risk-based approach to quality management at investigator sites.




Freedom Leaf Announces New Medical Advisory Board Members: Dr. Robert Melamede, Ph.D. and Dr. David Barton, MD., As It Plans For New Products In US and Internationally

Mon, 28 Nov 2016 06:30:00 EST

New opportunities explored for Freedom Leaf, Inc. to develop therapeutic nutraceutical cannabis/hemp products in the US and Internationally




ANGLE plc: Issue of Share Options

Mon, 28 Nov 2016 04:18:04 EST

GUILDFORD, SURREY--(Marketwired - Nov 28, 2016) - ANGLE plc (AIM: AGL) (OTCQX: ANPCY)




TopiVert receives IND approval for TOP1630 in the treatment of dry eye syndrome

Mon, 28 Nov 2016 02:00:00 EST

LONDON, UNITED KINGDOM--(Marketwired - Nov 28, 2016) -  TopiVert Pharma Ltd ("TopiVert" or the "Company"), a clinical-stage biotechnology company developing Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, locally-acting medicines for the treatment of chronic inflammatory diseases of the gastrointestinal (GI) tract and eye, announced today that its Investigational New Drug (IND) application for the evaluation of TOP1630 ophthalmic solution as a treatment of patients with dry eye syndrome (DES) has been approved by the US Food and Drug Administration (FDA).




Diet Doc Creates New Fat Blocking Prescription -- Orlean to Improve the Weight Loss Results of Paleo and Ketogenic Dieting

Mon, 28 Nov 2016 01:00:00 EST

ANCHORAGE, AK--(Marketwired - November 28, 2016) - Dr. Nishant Rao, Medical Director of Diet Doc Medical Weight Loss, states that his team at Diet Doc leans toward the Paleo Diet, the Ketogenic Diet and their exclusive Jumpstart Diet as blueprints for diet target macros for patients. These diet plans have resulted in patient weight loss of up to 20 pounds per month. In addition to diet planning, Diet Doc has created an exclusive, new pharmacy-grade prescription in order to combat the difficulties of managing The Paleo Diet and The Keto Diet via their own carefully formulated fat blocker, Orlean.




Diet Doc Releases Powerful Medical Weight Loss Program to Maximize Mediterranean Diet Results

Sun, 27 Nov 2016 01:00:00 EST

CHEYENNE, WY--(Marketwired - November 27, 2016) - Developing and maintaining a nutritionally balanced diet is a struggle, especially for the millions of Americans who are overweight or obese. Even with strict meal plans, losing weight and consuming exclusively healthy foods and drinks is difficult. According to a study by the Academy of Nutrition and Dietetics, the majority of Americans consume drinks and foods with low nutritional value and high amounts of fat, cholesterol, sugar and sodium. Struggling with excessive hunger between meals, uncontrollable cravings for junk food, and lack of adequate physical exercise, millions of individuals find it difficult to establish and maintain a healthy diet. This results in excessive weight gain, low energy levels and a variety of health issues like heart disease, type 2 diabetes, and hypertension. It is important, therefore, to moderate food as well as beverage consumption using a customized diet plan.